Vertex’s second try at a rare lung disorder
A small molecule for alpha-1 antitrypsin deficiency faces a key clinical test, and its chances of success aren’t good.
Recycling pays off for Mereo
The company has spent five years buying in discontinued projects, and at last has managed to sell one of these on at a nice profit.
Roche move endorses Iteos’s Tigit widget
A private Belgian biotech reckons Tigit is the new PD-1, a view Roche’s progress could validate.
Roche’s next immuno-oncology combo is a big bet on Tigit
Almost in stealth mode the Swiss firm moves to begin a huge pivotal programme rivalling that of the IDO and IL-2 mechanisms.
